Literature DB >> 10906637

Advances in specific immunotherapy of malignant melanoma.

C Curiel-Lewandrowski1, M F Demierre.   

Abstract

UNLABELLED: Management of malignant melanoma continues to present a challenge to dermatologists, particularly in advanced cases. In light of the steady increase in the worldwide incidence and mortality rates for melanoma, better understanding of the immune mechanisms regulating melanoma progression and interaction with the host's immune system seems eminently important. New studies on the role of immune mechanisms in the pathogenesis and clinical course of melanoma have recently been published. We review the immune mechanisms involved in tumor progression and ways in which these mechanisms may be applied toward immunotherapeutic management of malignant melanoma. LEARNING
OBJECTIVE: After the completion of this learning activity, participants should be familiar with (1) the immune mechanisms involved in host-tumor interaction and tumor rejection, (2) factors allowing the escape of melanoma cells from immune recognition, and (3) the current rationale for the different types of specific immunotherapy in melanoma. Better understanding of basic mechanisms in tumor immunology should raise awareness of future immunotherapeutic approaches in patients with melanoma, particularly in those who are at high risk of recurrence or who present with advanced disease.

Entities:  

Mesh:

Year:  2000        PMID: 10906637     DOI: 10.1067/mjd.2000.104513

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  3 in total

Review 1.  The Bacterial Ghost platform system: production and applications.

Authors:  Timo Langemann; Verena Juliana Koller; Abbas Muhammad; Pavol Kudela; Ulrike Beate Mayr; Werner Lubitz
Journal:  Bioeng Bugs       Date:  2010 Sep-Oct

2.  CD200 is induced by ERK and is a potential therapeutic target in melanoma.

Authors:  Kimberly B Petermann; Gabriela I Rozenberg; Daniel Zedek; Pamela Groben; Karen McKinnon; Christin Buehler; William Y Kim; Janiel M Shields; Shannon Penland; James E Bear; Nancy E Thomas; Jonathan S Serody; Norman E Sharpless
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

3.  Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases.

Authors:  P Radny; U M Caroli; J Bauer; T Paul; C Schlegel; T K Eigentler; B Weide; M Schwarz; C Garbe
Journal:  Br J Cancer       Date:  2003-11-03       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.